Deutsche Bank AG reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Friday. Deutsche Bank AG currently has a GBX 5,600 ($73.66) target price on the biopharmaceutical company’s stock.
AZN has been the subject of several other reports. Liberum Capital reaffirmed a buy rating and issued a GBX 4,800 ($63.13) price objective on shares of AstraZeneca plc in a research report on Tuesday, September 5th. HSBC Holdings plc increased their price objective on shares of AstraZeneca plc from GBX 4,100 ($53.93) to GBX 4,150 ($54.58) and gave the company a reduce rating in a research report on Monday, October 9th. UBS AG set a GBX 4,550 ($59.84) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Monday, October 23rd. Jefferies Group LLC increased their price target on shares of AstraZeneca plc from GBX 4,350 ($57.21) to GBX 4,800 ($63.13) and gave the stock a hold rating in a report on Monday, September 11th. Finally, Shore Capital reiterated a hold rating on shares of AstraZeneca plc in a report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (AZN) traded up GBX 68.50 ($0.90) during trading on Friday, hitting GBX 4,938.50 ($64.95). 1,257,664 shares of the company traded hands, compared to its average volume of 1,940,000. AstraZeneca plc has a 52-week low of GBX 3,996 ($52.56) and a 52-week high of GBX 5,520 ($72.60).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.